-
- Comment on:
-
N Engl J Med. 2006 Aug 31;355(9):873-84.
-
N Engl J Med. 2006 Aug 31;355(9):885-95.
Risks and benefits of celecoxib to prevent recurrent adenomas.
PMID: 16943408 [PubMed - indexed for MEDLINE]
-
Cited by 3 PubMed Central articles
-
Apoptosis in normal rectal mucosa, baseline adenoma characteristics, and risk of future adenomas.
Keku TO, Amin A, Galanko J, Martin C, Schliebe B, Sandler RS.
Cancer Epidemiol Biomarkers Prev. 2008 Feb; 17(2):306-10.
[Cancer Epidemiol Biomarkers Prev. 2008]
-
ReviewA review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia.
Cross JT, Poole EM, Ulrich CM.
Pharmacogenomics J. 2008 Aug; 8(4):237-47. Epub 2008 Jan 15.
[Pharmacogenomics J. 2008]
-
Celecoxib modulates adhesion of HT29 colon cancer cells to vascular endothelial cells by inhibiting ICAM-1 and VCAM-1 expression.
Dianzani C, Brucato L, Gallicchio M, Rosa AC, Collino M, Fantozzi R.
Br J Pharmacol. 2008 Mar; 153(6):1153-61. Epub 2007 Dec 17.
[Br J Pharmacol. 2008]